Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $414,043.52 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 36,256 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $11.42, for a total transaction of $414,043.52. Following the completion of the transaction, the executive vice president now owns 735,074 shares in the company, valued at $8,394,545.08. The trade was a 4.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

David Sponsel also recently made the following trade(s):

• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The shares were sold at an average price of $10.71, for a total value of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The stock was sold at an average price of $10.00, for a total value of $2,380.00.

Alphatec Price Performance

Shares of ATEC opened at $11.42 on Friday. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The company has a market cap of $1.62 billion, a P/E ratio of -8.92 and a beta of 1.43. The firm’s 50 day moving average price is $10.26 and its 200 day moving average price is $8.13. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $17.34.

Analyst Upgrades and Downgrades

ATEC has been the subject of a number of research analyst reports. Needham & Company LLC increased their price target on Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research report on Tuesday, January 14th. Finally, Barclays upped their price objective on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.56.

Institutional Trading of Alphatec

Several hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in shares of Alphatec in the 4th quarter valued at approximately $358,000. M&T Bank Corp purchased a new stake in shares of Alphatec during the 4th quarter worth $170,000. Atria Investments Inc grew its stake in shares of Alphatec by 20.3% during the fourth quarter. Atria Investments Inc now owns 23,585 shares of the medical technology company’s stock worth $217,000 after purchasing an additional 3,976 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Alphatec by 2.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 846,224 shares of the medical technology company’s stock valued at $7,768,000 after buying an additional 23,002 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. acquired a new stake in Alphatec in the fourth quarter valued at $106,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.